Corporate Information

A global cannabis company

Based in Latin America

TSXV: KHRN | OTC: KHRNF | Frankfurt: A2JMZC

Our Patients And Consumers
Come First

VERTICALLY INTEGRATED

LEARN MORE ABOUT KHIRON’S FACILITY

THROUGH OUR VERTICALLY INTEGRATED PROCESS, WE INVEST IN QUALITY AT EVERY STEP OF THE WAY.

Our Facilities

  • Khiron currently owns and operates state of the art medical cannabis cultivation and processing facilities in Latin America.
  • Facilities include a 14,000 sq ft GMP compliant extraction lab and ISO 17025 compliant testing lab in Colombia. In addition, a 105,486 sq ft GAP and GMP cultivation and processing facility is currently under construction In Uruguay.

State-of-the-art, 14,000 square foot GMP compliant cannabis extraction lab and ISO 17025 compliant cannabis testing lab include full capabilities in Ultra high and High performance liquid chromatography ("UHPLC" & "HPLC") technology, gas chromatography, stability testing, microbiology and heavy metals testing.

Physical chemical cannabis testing lab has a capacity of up to 70 daily UHPLC & HPLC cannabinoid samples, 15 daily gas chromatography samples, and 2,000 monthly heavy metals samples. Microbiological testing lab has a capacity of up to 20 daily samples.

State-of-the-art testing lab allows the Company to fully test every aspect of its vertical integration from soil and water, to flower to extract, ensuring a high-quality product that will be delivered to patients across Latin America.

Cultivation capabilities operate within the most up-to-date country THC quotas assigned by the International Narcotics Control Board (INCB) to meet domestic demand, including treatment of more than 119,000 patients at the Company's ILANS clinics.

Facility in Juan Lacaze includes plans for a GAP-compliant 8,000 m2 (86,111 sq ft) cultivation area and a GMP-compliant 1,800 m2 (19,375 sq.ft) processing plant, with a production capacity of 17 tons per year.

The Uruguay facility will increase Khiron's total production capacity and strengthens ability to export and supply cannabis across the Mercosur trading bloc, with access to Brazil and Europe.

The cultivation area and processing plant will be built to meet the requirements of Good Agricultural Practices (GAP) and Good Manufacturing Practices (GMP), respectively, in keeping with Khiron's continued expertise and core commitment to regulatory and operational compliance.

Branded Products

Medical Products

Khiron’s portfolio of more than 20 THC and CBD strains already registered with the Colombian Agricultural Institute (ICA), is key to building  agronomic and chemical profiles to treat a variety of medical conditions.

Consumer Packaged Goods & Skincare

At the core of Khiron’s wellness unit, Kuida® cosmeceuticals, the first mass-market branded CBD skincare line in Latin America, is distributed at retail and online across Colombia and in permissive Stated in the United States.

Khiron will introduce the Aceso™ Hemp brand to the Latin America market, with initial sales beginning in Q4 2019 in Colombia.

Learn more

Khiron’s Global Network

We’re proud to be partnering with international brands that share our passion. Learn more about how our CPG brands around the world make a difference.

  1. Kuida: Cosmeceutical business line, sold in +300 point of sales of Colombia
  2. Magistral Preparations: Medical business line, prescribed in Khiron’s ILANS and Zerenia clinics
  3. Acceso: Supplements business line

  1. Kuida: sold in Los Angeles, CA at CannabisNow

  1. Kuida: Cosmeceutical product line, fulfilled E.U. cosmetic product regulatory requirements for 7 SKU´s

Multi-Billion Global Market with First Mover Advantage in LatAm

Our goals go beyond building a great cultivation facility. We aim to become the global leader in creating high quality, consumer packaged goods (CPG) cannabis brands around the world.

With regulatory change happening rapidly across Latin America, eleven countries have legalized medical cannabis, and three have decriminalized the use of personal amounts. With operations in Colombia, a presence in Mexico, Uruguay, Chile and Peru, and access to Brazil, Khiron Life Sciences is positioned to be a leading, established player providing investor exposure to the Latin American market.

Our experienced European management team provides Khiron with a strong cannabis industry background in capital markets and regulatory matters. The company currently has fulfilled E.U. cosmetic product regulatory requirements for seven Kuida® products to be launched in the UK.  The company  has also entered into an agreement to be the exclusive Latin American provider of cannabis medicines to Project Twenty21 in the UK. The company is set  for growth in Europe, with significant near- and long-term revenue opportunities thatvalidate the company's management, execution abilities and global strategy.

Our Clinics

In the domestic market of Colombia and elsewhere in Latin America, Khiron Life Sciences has built partnerships with some of the region’s most respected medical associations. In coordination with these associations, a growing regional network of physicians is being created to serve as the primary distribution channel.

Leadership

Leadership

Khiron Life Sciences has a highly experienced management team and influential board representation including the 55th president of Mexico and former CEO of Coca Cola Mexico, Vicente Fox, and global retail brand entrepreneur Joseph Mimran who sits on the board of the Company’s Colombia subsidiary


View Management Team

View Board of Directors

Contact Us

(+1) 647-360-7582

Have business-related questions about KHRN? Or just general inquiries? Send us a message or give us a call and we ́ll be happy to help. We’re available by phone from Mon-Fri 9am – 5pm EST to answer any of your questions

Register Now

Be the first to try our products when they become available. Read our Privacy Policy.

Sign up for Email Alerts